Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATAI atai Life Sciences	$2.20 -2.2%	$1.92	$1.03 ▼ $2.64	$440.75M	1.47	1.74 million shs	963,664 shs
AUPH Aurinia Pharmaceuticals	$8.64 +0.1%	$8.09	$5.20 ▼ $10.67	$1.17B	1.15	1.35 million shs	4.36 million shs
BGM BGM Group	$11.97 -6.6%	$12.57	$5.26 ▼ $17.17	$1.16B	1.38	33,793 shs	86,258 shs
ELVN Enliven Therapeutics	$20.68 -3.9%	$19.32	$13.30 ▼ $30.03	$1.01B	0.79	289,643 shs	1.44 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATAI atai Life Sciences	0.00%	-11.29%	-3.08%	+61.76%	+65.41%
AUPH Aurinia Pharmaceuticals	0.00%	+11.20%	+9.92%	+7.46%	+51.31%
BGM BGM Group	0.00%	-8.42%	-10.54%	+4.63%	+1,196,999,900.00%
ELVN Enliven Therapeutics	0.00%	-2.91%	+15.92%	+5.08%	-11.51%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATAI atai Life Sciences	2.9069 of 5 stars	3.7	3.0	0.0	0.0	2.5	1.7	0.6
AUPH Aurinia Pharmaceuticals	2.5325 of 5 stars	3.5	1.0	0.0	0.0	2.1	0.8	1.9
BGM BGM Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ELVN Enliven Therapeutics	2.2326 of 5 stars	3.5	0.0	0.0	0.0	2.5	4.2	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATAI atai Life Sciences	3.33	Buy	$8.67	293.94% Upside
AUPH Aurinia Pharmaceuticals	3.00	Buy	$11.50	33.10% Upside
BGM BGM Group	0.00	N/A	N/A	N/A
ELVN Enliven Therapeutics	3.00	Buy	$39.60	91.49% Upside

Current Analyst Ratings Breakdown

Latest ATAI, AUPH, BGM, and ELVN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/16/2025	ELVN Enliven Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$40.00 ➝ $52.00
6/16/2025	ELVN Enliven Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$37.00
5/20/2025	ATAI atai Life Sciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$5.00
5/20/2025	ATAI atai Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/16/2025	ELVN Enliven Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $27.00
5/15/2025	ELVN Enliven Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$39.00 ➝ $40.00
5/13/2025	ATAI atai Life Sciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATAI atai Life Sciences	$310K	1,421.77	N/A	N/A	$0.69 per share	3.19
AUPH Aurinia Pharmaceuticals	$235.13M	4.96	$0.31 per share	28.01	$2.68 per share	3.22
BGM BGM Group	$25.10M	46.36	N/A	N/A	$7.34 per share	1.63
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	$6.34 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATAI atai Life Sciences	-$149.27M	-$0.91	N/A	N/A	N/A	N/A	-102.10%	-77.55%	8/12/2025 (Estimated)
AUPH Aurinia Pharmaceuticals	$5.75M	$0.28	30.86	15.43	N/A	16.11%	14.27%	9.93%	7/30/2025 (Estimated)
BGM BGM Group	-$1.44M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ELVN Enliven Therapeutics	-$89.02M	-$1.92	N/A	N/A	N/A	N/A	-31.84%	-30.09%	8/12/2025 (Estimated)

Latest ATAI, AUPH, BGM, and ELVN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ATAI atai Life Sciences	-$0.19	-$0.15	+$0.04	-$0.15	N/A	$1.56 million
5/14/2025	Q1 2025	ELVN Enliven Therapeutics	-$0.51	-$0.57	-$0.06	-$0.57	N/A	N/A
5/12/2025	Q1 2025	AUPH Aurinia Pharmaceuticals	$0.08	$0.16	+$0.08	$0.16	$61.06 million	$62.47 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATAI atai Life Sciences	N/A	N/A	N/A	N/A	N/A
AUPH Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BGM BGM Group	N/A	N/A	N/A	N/A	N/A
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATAI atai Life Sciences	0.08	4.07	4.07
AUPH Aurinia Pharmaceuticals	0.16	5.93	5.26
BGM BGM Group	N/A	3.39	2.82
ELVN Enliven Therapeutics	N/A	21.07	21.06

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATAI atai Life Sciences	28.41%
AUPH Aurinia Pharmaceuticals	36.83%
BGM BGM Group	N/A
ELVN Enliven Therapeutics	95.08%

Insider Ownership

Company	Insider Ownership
ATAI atai Life Sciences	26.80%
AUPH Aurinia Pharmaceuticals	12.20%
BGM BGM Group	58.66%
ELVN Enliven Therapeutics	25.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATAI atai Life Sciences	80	200.34 million	146.65 million	Optionable
AUPH Aurinia Pharmaceuticals	300	135.10 million	118.62 million	Optionable
BGM BGM Group	298	97.22 million	40.19 million	N/A
ELVN Enliven Therapeutics	50	49.07 million	36.36 million	Optionable

ATAI, AUPH, BGM, and ELVN Headlines

Recent News About These Companies

Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Sells 12,500 Shares of Stock

June 24, 2025 | marketbeat.com

Enliven Short Interest Falls To 14-Month Low After Leukemia Trial Data, Goldman Initiates With ‘Buy’

June 23, 2025 | msn.com

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Sells $277,250.00 in Stock

June 18, 2025 | marketbeat.com

Goldman Sachs initiates Enliven Therapeutics stock with Buy rating

June 17, 2025 | investing.com

Enliven grosses $230M from stock sale

June 17, 2025 | bizwest.comB

Enliven Therapeutics, Inc. (ELVN) Backed by Goldman Sachs After Strong Trial Data

June 17, 2025 | msn.com

Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

June 16, 2025 | prnewswire.com

Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Up Following Analyst Upgrade

June 16, 2025 | marketbeat.com

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Consensus Rating of "Buy" from Analysts

June 16, 2025 | marketbeat.com

Robert W. Baird Issues Positive Forecast for Enliven Therapeutics (NASDAQ:ELVN) Stock Price

June 16, 2025 | marketbeat.com

Enliven Therapeutics (NASDAQ:ELVN) Coverage Initiated by Analysts at The Goldman Sachs Group

June 16, 2025 | marketbeat.com

Enliven Therapeutics Announces $200 Mln Offering Of Common Stock, Pre-Funded Warrants

June 15, 2025 | nasdaq.com

Enliven Prices $200 Million Public Offering Amid Positive Readout in ELVN-001 CML Trial

June 13, 2025 | precisionmedicineonline.comP

Enliven Therapeutics stock falls after pricing capital raise of $200M via securities offering

June 13, 2025 | msn.com

Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Down - Should You Sell?

June 13, 2025 | marketbeat.com

Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

June 13, 2025 | prnewswire.com

Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

June 13, 2025 | prnewswire.com

Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress

June 13, 2025 | prnewswire.com

Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel Sells 6,667 Shares

June 12, 2025 | insidertrades.com

Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells 6,667 Shares of Stock

June 11, 2025 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $984,000 Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

June 11, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATAI, AUPH, BGM, and ELVN Company Descriptions

atai Life Sciences NASDAQ:ATAI

$2.20 -0.05 (-2.22%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.22 +0.02 (+1.09%)

As of 05:31 AM Eastern

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Aurinia Pharmaceuticals NASDAQ:AUPH

$8.64 +0.01 (+0.12%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$8.82 +0.18 (+2.08%)

As of 05:21 AM Eastern

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

BGM Group NASDAQ:BGM

$11.97 -0.85 (-6.63%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$12.45 +0.48 (+4.04%)

As of 05:15 AM Eastern

Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.

Enliven Therapeutics NASDAQ:ELVN

$20.68 -0.84 (-3.90%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$20.54 -0.14 (-0.68%)

As of 04:46 AM Eastern

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time